It's the first combination of 2 classes of medications, the GIP and GLP-1 receptor agonist which are both incretin hormones that are released after food intake
Both drugs contain tirzepatide as the active ingredient, but Mounjaro is approved to treat Type 2 diabetes, while Zepbound is approved for weight loss and obstructive sleep apnea in adults with obesity
One such breakthrough in medical science is Semaglutide, a medication initially designed for managing type 2 diabetes and weight loss
This is the best route if you have underlying health conditions or want to discuss how B12 fits into your broader health plan
3 Previous randomized control trials of semaglutide in diabetic and non-diabetic populations have suggested that non-diabetic patients lose more weight than diabetic patients when prescribed semaglutide, but those studies do not represent real-world data and did not evaluate doses lower than 2.4 mg
The Q statistic was calculated using a chi-square analysis to assess heterogeneity among combined results